Coherus reported that its proposed adalimumab (Humira) biosimilar candidate demonstrated clinical equivalence on all endpoints compared to the European marketed Humira. The candidate in this study also did not show any clinically meaningful difference in adverse events.
These results came from the first of three ongoing pharmacokinetic bioequivalence studies. This study included 216 healthy subjects who received single 40 mg doses sub-cutaneously.
